feed,title,long_url,short_url
Benzinga,Melanoma Study Achieves Key Milestone as Bristol's Flagship Treatment Secures Improvement in Survival Rates,https://benzinga.com/general/biotech/22/09/28885410/bristol-myers-squibbs-flagship-cancer-drug-shows-recurrence-free-survival-benefit-in-skin-cancer-,https://bit.ly/3df0Mc4
